



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/776,934
				Filing Date	February 10, 2004
				First Named Inventor	HANSEN, Bo
				Group Art Unit	1632
				Examiner Name	CHONG, Kimberly
				Confirmation No.	2105
Sheet	1	of	3	Attorney Docket No.	366929-018US (396515)

U.S. PUBLISHED DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Publication Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	A1	US-5,227,400		Holton et al.	07-13-1993
	A2	US-5,248,796		Chen et al.	09-28-1993
	A3	US-5,250,683		Holton et al.	10-05-1993
	A4	US-5,254,580		Chen et al.	10-19-1993
	A5	US-5,272,171		Yasutsugu et al.	12-21-1993
	A6	US-5,278,324		Kingston et al.	01-11-1994

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ²	
		Office	Number	Kind Code (if known)			Yes	No
	B1	EP	0 253 739	B1	10-11-1989			X
	B2	WO	1992/09589	A1	06-11-1992			
	B3	WO	1993/18210	A1	09-16-1993			
	B4	WO	1999/14226	A2	03-25-1999			
	B5	WO	2000/56746	A2	09-28-2000			
	B6	WO	2000/56748	A1	09-28-2000			
	B7	WO	2000/66604	A2	11-09-2000			
	B8	WO	2001/25248	A2	04-12-2001			
	B9	WO	2002/094250	A2	11-28-2002			
	B10	WO	2002/28875	A2	04-11-2002			
	B11	WO	2003/006475	A2	01-23-2003			
	B12	WO	2004/069991	A2	08-19-2004			

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/776,934
				Filing Date	February 10, 2004
				First Named Inventor	HANSEN, Bo
				Group Art Unit	1632
				Examiner Name	CHONG, Kimberly
				Confirmation No.	2105
Sheet	2	of	3	Attorney Docket No.	366929-018US (396515)

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ²		
			Yes	No	
	C1	BEAUCAGE et al., 1992, "Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach," <i>Tetrahedron</i> , 48(12):2223-2311			
	C2	BEAUCAGE et al., 1993, "The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications," <i>Tetrahedron</i> , 49(28):6123-6194			
	C3	BROWN et al., 1991, "In Oligonucleotides and Analogues. A Practical Approach," Oxford: IRL 13-14			
	C4	CAO et al., 2004, "XIAP and Survivin as Therapeutic Targets for Radiation Sensitization in Preclinical Models of Lung Cancer," <i>Oncogene</i> , 23:1-6			
	C5	CROOKE, R.M., 1997, "In Vitro Cellular Uptake, Distribution and Metabolism of Oligonucleotides," <i>Antisense Res. and Application</i> 131:103-140			
	C6	DEAN et al., 1994, "Inhibition of Protein Kinase C-α Expression in Human A549 Cells by Antisense Oligonucleotides Inhibits Induction of Intercellular Adhesion Molecule 1 (ICAM-1) mRNA by Phorbol Esters," <i>J. Biol. Chem.</i> , 269(23):16416-16424			
	C7	HOLMES et al., 1991, "Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer," <i>J. Natl. Cancer Inst.</i> , 83(24):1797-1805			
	C8	HOLTON et al., 1994, "First Total Synthesis of Taxol. I. Functionalization of the B Ring," <i>J. Am. Chem. Soc.</i> , 116(4):1597-1598			
	C9	KOHN et al., 1994, "Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer," <i>J. Natl. Cancer Inst.</i> , 86(1):18-24			
	C10	LEAMON et al., 1991, "Delivery of Macromolecules into Living Cells: A Method that Exploits Folate Receptor Endocytosis," <i>Proc. Nat. Acad. Sci.</i> , 88:5572-5576			
	C11	LU et al., 2004, "Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer," <i>Cancer Research</i> , 64:2840-2845			
	C12	MCGUIRE et al., 1989 "Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms." <i>Ann. Intern. Med.</i> 111: 273-279.			
	C13	NICOLAOU et al., 1994, "Total Synthesis of Taxol," <i>Nature</i> 367:630-634			
	C14	Office Action from US Serial No. 11/272,124, dated 05-16-2008 (Docket No. 366929-024US)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/776,934
				Filing Date	February 10, 2004
				First Named Inventor	HANSEN, Bo
				Group Art Unit	1632
				Examiner Name	CHONG, Kimberly
				Confirmation No.	2105
Sheet	3	of	3	Attorney Docket No.	366929-018US (396515)

	C15	WAGNER et al., 1990, "Transferrin-Polycation Conjugates as Carriers for DNA Uptake into Cells," <i>Proc. Nat. Acad. Sci.</i> , 87:3410-3414		
	C16	WANG et al., 2003, "Survivin Antisense RNA Enhances Taxol-Induced Apoptosis in Leukemia Cell Line HL-60," <i>Zhonghua Xue Ye Xue Za Zhi</i> . 24(7):351-54		
	C17	ZANGEMEISTER-WITTKE, 2003, "Antisense to Apoptosis Inhibitors Facilitates Chemotherapy and TRAIL-Induced Death Signaling," <i>Ann. N.Y. Acad. Sci.</i> 1002:90-94		

14260519.1.BUSINESS

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.